ReShape Current Deferred Revenue from 2010 to 2025
| RSLS Stock | USD 0.66 0.04 5.71% |
Current Deferred Revenue | First Reported 2009-06-30 | Previous Quarter 643 K | Current Value 318 K | Quarterly Volatility 3 M |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.19, Dividend Yield of 0.0 or PTB Ratio of 0.24. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Current Deferred Revenue |
Latest ReShape Lifesciences' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of ReShape Lifesciences over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. ReShape Lifesciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
ReShape Current Deferred Revenue Regression Statistics
| Arithmetic Mean | (1,042,314) | |
| Geometric Mean | 199,458 | |
| Coefficient Of Variation | (269.26) | |
| Mean Deviation | 2,022,296 | |
| Median | 53,130 | |
| Standard Deviation | 2,806,561 | |
| Sample Variance | 7.9T | |
| Range | 9.3M | |
| R-Value | 0.54 | |
| Mean Square Error | 6T | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | 318,494 | |
| Total Sum of Squares | 118.2T |
ReShape Current Deferred Revenue History
About ReShape Lifesciences Financial Statements
ReShape Lifesciences shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 50.6 K | 53.1 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.